Home › All Companies › ATOS › Annual Report

ATOSSA THERAPEUTICS, INC. (ATOS) — Annual Report

AI-Powered SEC Filing Analysis

← All ATOS filings
Latest Annual Report Filed: 2026-03-25

Key Insights

  • Atossa Therapeutics, Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, providing an update on its financial performance and business operations.
  • The company reported an increase in research and development expenses, likely due to continued investment in its pipeline of therapeutic candidates.
  • Atossa Therapeutics disclosed several subsequent events, including an at-the-market offering and a reverse stock split, which may impact the company's capital structure and share price.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-25. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for ATOSSA THERAPEUTICS, INC.

Current Report Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.